Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 11,245 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total transaction of $180,257.35. Following the completion of the sale, the insider now directly owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Day One Biopharmaceuticals Trading Up 4.0 %

DAWN stock opened at $16.39 on Friday. The firm has a 50 day moving average of $14.34 and a 200-day moving average of $14.41. The firm has a market capitalization of $1.65 billion, a P/E ratio of -15.91 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 12 month low of $10.90 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter last year, the firm earned ($0.54) earnings per share. Sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in DAWN. Janus Henderson Group PLC raised its position in shares of Day One Biopharmaceuticals by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after buying an additional 336,281 shares in the last quarter. AQR Capital Management LLC raised its position in Day One Biopharmaceuticals by 517.0% during the second quarter. AQR Capital Management LLC now owns 113,020 shares of the company’s stock valued at $1,557,000 after purchasing an additional 94,703 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after buying an additional 1,447 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in Day One Biopharmaceuticals by 65.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in Day One Biopharmaceuticals in the third quarter worth approximately $2,566,000. 87.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DAWN has been the topic of a number of research reports. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.